Whalen C C, Nsubuga P, Okwera A, Johnson J L, Hom D L, Michael N L, Mugerwa R D, Ellner J J
Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-4945, USA.
AIDS. 2000 Jun 16;14(9):1219-28. doi: 10.1097/00002030-200006160-00020.
Retrospective cohort studies of tuberculosis suggest that active tuberculosis accelerates the progression of HIV infection. The validity of these findings has been questioned because of their retrospective design, diverse study populations, variable compliance with anti-tuberculous therapy and use of anti-retroviral medication. To assess the impact of tuberculosis on survival in HIV infection we performed a prospective study among HIV-infected Ugandan adults with and without tuberculosis.
In a prospective cohort study, 230 patients with HIV-associated tuberculosis and 442 HIV-infected subjects without tuberculosis were followed for a mean duration of 19 months for survival. To assess changes in viral load over 1 year, 20 pairs of tuberculosis cases and controls were selected and matched according to baseline CD4 lymphocyte count, age, sex and tuberculin skin test status.
During the follow-up period, 63 out of of 230 tuberculosis cases (28%) died compared with 85 out of 442 controls (19%), with a crude risk ratio of 1.4 [95% confidence interval (CI), 1.07-1.87]. Most deaths occurred in patients with CD4 lymphocyte counts < 200 x 10(6) cells/l at baseline (n = 99) and occurred with similar frequency in the tuberculosis cases (46%) and the controls (44%). When the CD4 lymphocyte count was > 200 x 10(6)/l, however, the relative risk of death in HIV-associated tuberculosis was 2.1 (95% CI, 1.27-3.62) compared with subjects without tuberculosis. For subjects with a CD4 lymphocyte count > 200 x 10(6)/l, the 1-year survival proportion was slightly lower in the cases than in the controls (0.91 versus 0.96), but by 2 years the survival proportion was significantly lower in the cases than in the controls (0.84 versus 0.91; P < 0.02; log-rank test). For subjects with a CD4 lymphocyte count of 200 x 10(6) cells/l or fewer, the survival proportion at 1 year for the controls was lower than cases (0.59 versus 0.64), but this difference was not statistically significant (P = 0.53; logrank test). After adjusting for age, sex, tuberculin skin test status, CD4 lymphocyte count, and history of HIV-related infections, the overall relative hazard for death associated with tuberculosis was 1.81 (95% CI, 1.24-2.65). In a nested Cox regression model, the relative hazard for death was 3.0 (95% CI, 1.62-5.63) for subjects with CD4 lymphocyte counts > 200 x 10(6)/l and 1.5 (95% CI, 0.99-2.40) for subjects with a CD4 lymphocyte count of 200 x 10(6)/l or fewer.
The findings from this prospective study indicate that active tuberculosis exerts its greatest effect on survival in the early stages of HIV infection, when there is a reserve capacity of the host immune response. These observations provide a theoretical basis for the treatment of latent tuberculous infection in HIV-infected persons.
结核病的回顾性队列研究表明,活动性结核病会加速HIV感染的进展。由于这些研究的回顾性设计、多样的研究人群、抗结核治疗的依从性差异以及抗逆转录病毒药物的使用情况,这些研究结果的有效性受到了质疑。为了评估结核病对HIV感染患者生存的影响,我们在乌干达成年HIV感染者中开展了一项前瞻性研究,这些患者中有结核病患者,也有未患结核病的患者。
在一项前瞻性队列研究中,对230例HIV相关结核病患者和442例未患结核病的HIV感染者进行了为期19个月的生存随访。为了评估1年内病毒载量的变化,选取了20对结核病病例和对照,并根据基线CD4淋巴细胞计数、年龄、性别和结核菌素皮肤试验状态进行匹配。
在随访期间,230例结核病患者中有63例(28%)死亡,而442例对照中有85例(19%)死亡,粗略风险比为1.4[95%置信区间(CI),1.07 - 1.87]。大多数死亡发生在基线CD4淋巴细胞计数<200×10⁶细胞/升的患者中(n = 99),在结核病病例(46%)和对照(44%)中的发生频率相似。然而,当CD4淋巴细胞计数>200×10⁶/升时,与未患结核病的受试者相比,HIV相关结核病患者的相对死亡风险为2.1(95%CI,1.27 - 3.62)。对于CD4淋巴细胞计数>200×10⁶/升的受试者,病例组1年生存率略低于对照组(0.91对0.96),但到2年时,病例组生存率显著低于对照组(0.84对0.91;P<0.02;对数秩检验)。对于CD4淋巴细胞计数为200×10⁶细胞/升或更低的受试者,对照组1年生存率低于病例组(0.59对0.64),但差异无统计学意义(P = 0.53;对数秩检验)。在调整了年龄、性别、结核菌素皮肤试验状态、CD4淋巴细胞计数和HIV相关感染史后,与结核病相关的总体死亡相对风险为1.81(95%CI,1.24 - 2.65)。在嵌套Cox回归模型中,CD4淋巴细胞计数>200×10⁶/升的受试者死亡相对风险为3.0(95%CI,1.62 - 5.63),CD4淋巴细胞计数为200×10⁶细胞/升或更低的受试者死亡相对风险为1.5(95%CI,0.99 - 2.40)。
这项前瞻性研究的结果表明,活动性结核病在HIV感染早期对生存影响最大,此时宿主免疫反应有储备能力。这些观察结果为治疗HIV感染者的潜伏结核感染提供了理论依据。